Ajanta Pharma Ltd

- There is no explicit mention of any current or future fundraising through debt or equity in the provided transcript. - The company discussed capital expenditure plans for FY2027, expecting to increase capex to around Rs. 400 crores (including Rs. 150 crores for maintenance and balance for new capacity expansion), but did not specify the source of funding. - Trade receivables days increased to 125 days, partly due to a shift from factoring to working capital loans, suggesting some utilization of debt for working capital but no indication of new debt raising. - Promoters have some pledged shares, but this pledge is for personal/business reasons of two promoter brothers, not related to company borrowing. - Overall, no announcement or indication of planned equity or debt fundraising was made.

- Capital expenditure for FY 2026 stood at Rs. 330 crores, in line with guidance. - Ajanta Pharma is embarking upon a new capex cycle to meet continued growth requirements. - For FY 2027, capex is expected to increase to around Rs. 400 crores. - Of this, Rs. 150 crores is allocated for maintenance, and the balance for new capacity expansion. - The company is investing in product range expansion and addition of medical representatives across geographies. - Increased filing activities are planned, leading to a slight rise in R&D costs. - Strategic investments also include a focus on digitalization and AI to improve efficiencies, but no significant near-term impact on R&D expenses is expected.

- India business is expected to grow at mid-teens (around 16-18%) in FY27. - Asia business is guided for high double-digit growth next year, recovering from logistics delays. - Africa business targeted for high double-digit growth. - US generics business to grow at mid-single digit in the coming year after strong 49% growth in FY26. - Chronic therapy areas (around 50% of combined Asia and Africa branded generics market) will remain a focus. - Gynaecology segment in India showing encouraging progress, expected to contribute meaningfully over next 2-3 years. - Nephrology segment in India developing slowly, positive signs but longer gestation. - Overall company targeting revenue growth in the high teens (~16-18%) for FY27. - Growth driven by volume increase, price growth, and new product launches (new products contributed 4.7% growth in FY26). - Addition of medical representatives planned to support growth across therapies and geographies.

- Ajanta Pharma expects high-teens revenue growth for FY27, approximately 16%-18%. - EBITDA margin guidance for FY27 is around 27% (±1%), slightly lower than FY26's 27.7%, due to ongoing investments in market expansion, product range, MR additions, and increased R&D filings. - PAT margin is expected to remain steady around 19%, similar to FY26. - R&D spend is expected to stay around 5% of total revenue. - Effective tax rate will increase due to a manufacturing facility transitioning out of its tax exemption. - The company projects mid-single-digit growth in the U.S. market for FY27 following a strong 49% growth in FY26. - Asia business is expected to recover with high double-digit growth in FY27 after FY26's supply chain-induced dip. - India business growth is targeted in mid-teens, supported by ongoing MR additions and new product launches.

The provided pages from Ajanta Pharma Limited's May 05, 2026 report do not mention any details regarding the current or expected order book or pending orders. The discussion focuses primarily on revenue growth, therapy areas, market performance, cost impacts, digitalization, sales force additions, and margins. There is no specific information provided about order book status or pending orders in the extracted content.